Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celcuity Inc. on May 1, 2026. The filing discloses positive topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial. The trial evaluates gedatolisib plus fulvestrant, with or without palbociclib, in patients with hormone receptor positive (HR+), HER2-negative, PIK3CA mutant locally advanced or metastatic breast cancer following progression on prior therapies.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory strategy rather than financial performance data.
Material Changes and Clinical Results
- Primary Efficacy: The combination of gedatolisib, fulvestrant, and palbociclib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to alpelisib plus fulvestrant.
- Secondary Endpoint: The regimen of gedatolisib plus fulvestrant (without palbociclib) also showed a statistically significant and clinically meaningful improvement in PFS compared to alpelisib plus fulvestrant.
- Safety Profile: Both gedatolisib regimens were generally well tolerated with manageable safety profiles and no new safety signals identified.
Outlook, Management Commentary, and Risks
Management intends to submit these data to the U.S. Food and Drug Administration (FDA) as a supplemental New Drug Application (sNDA). The company also plans to present the data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and submit data to other regulatory authorities following the sNDA submission.
The filing includes standard forward-looking statement disclaimers. Key risks include the potential for data changes following comprehensive review, unforeseen delays in clinical trials or FDA review, the ability to obtain regulatory approval, market acceptance of gedatolisib, competition from other therapies, and the ability to access capital on favorable terms.
Investor Verification Checklist
- Verify the full statistical data and confidence intervals for the PFS improvements in the VIKTORIA-1 trial upon the release of the full clinical study report.
- Confirm the specific PDUFA goal date assigned by the FDA for the anticipated sNDA submission.
- Monitor the presentation of data at the 2026 ASCO Annual Meeting for peer review and additional safety details.
- Review the company's most recent Form 10-K for detailed financial position, cash runway, and capital requirements.
- Assess the competitive landscape regarding alpelisib and other PI3K inhibitors in the HR+/HER2- breast cancer market.